Kevin Kalinsky

4.1k total citations · 1 hit paper
107 papers, 1.9k citations indexed

About

Kevin Kalinsky is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kevin Kalinsky has authored 107 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 58 papers in Pulmonary and Respiratory Medicine and 33 papers in Cancer Research. Recurrent topics in Kevin Kalinsky's work include Advanced Breast Cancer Therapies (46 papers), HER2/EGFR in Cancer Research (26 papers) and Cancer Treatment and Pharmacology (25 papers). Kevin Kalinsky is often cited by papers focused on Advanced Breast Cancer Therapies (46 papers), HER2/EGFR in Cancer Research (26 papers) and Cancer Treatment and Pharmacology (25 papers). Kevin Kalinsky collaborates with scholars based in United States, Spain and France. Kevin Kalinsky's co-authors include Dawn L. Hershman, Prabhjot S. Mundi, Carolyn K. McCourt, Jasgit C. Sachdev, Katherine D. Crew, Matthew Maurer, Heather Greenlee, Alfred I. Neugut, Danielle Awad and Meghna S. Trivedi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Kevin Kalinsky

103 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer

2025 16 citations Komal Jhaveri, Seock‐Ah Im et al. profile →

Peers

Countries citing papers authored by Kevin Kalinsky

Since Specialization

Citations

This map shows the geographic impact of Kevin Kalinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Kalinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Kalinsky more than expected).

Fields of papers citing papers by Kevin Kalinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Kalinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Kalinsky. The network helps show where Kevin Kalinsky may publish in the future.

Co-authorship network of co-authors of Kevin Kalinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Kalinsky. A scholar is included among the top collaborators of Kevin Kalinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Kalinsky. Kevin Kalinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tackling the Cardio-Kidney-Metabolic Burden in Cancer 2025 ·Current Atherosclerosis Reports ·(unknown), Viraj Shah, (unknown), Omar Mohamed Makram, Ola S. Ahmed, (unknown), (unknown), (unknown), (unknown), (unknown), Kevin Kalinsky, Anita Deswal, Diego Sadler, Vipul C. Chitalia, Neal L. Weintraub, Avirup Guha	0
2	First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. 2024 ·Journal of Clinical Oncology ·Dejan Juric, Kevin Kalinsky, Nicholas C. Turner, Komal Jhaveri, Peter Schmid, Sherene Loi, Cristina Saura, Seock‐Ah Im, Patrapim Sunpaweravong, Huiping Li, Antonino Musolino, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, (unknown), Guiyuan Lei, Jacob Devine, Thomas J. Stout, Sibylle Loibl	23
3	Abstract PO1-10-04: Racial and Ethnic Disparities in Anthracycline and HER2-targeted Cardiotoxicity in Patients With Breast Cancer Using Global Longitudinal Strain Imaging Techniques 2024 ·Cancer Research ·Ying Wang, J. Raikhelkar, (unknown), (unknown), Neil Vasan, Meghna S. Trivedi, Kevin Kalinsky, Katherine D. Crew, Melissa Beauchemin, Jason D. Wright, Dawn L. Hershman, Melissa Accordino	1
4	Abstract PS02-01: Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials 2024 ·Cancer Research ·Lowell L. Hart, Seock‐Ah Im, Sara M. Tolaney, Mario Campone, Timothy Pluard, Berta Sousa, Gilles Freyer, (unknown), Kevin Kalinsky, (unknown), Melissa Gao, Huilin Hu, Sherko Küemmel	1
5	Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial. 2024 ·Journal of Clinical Oncology ·Rebecca Shatsky, Meghna S. Trivedi, Coral Omene, Kevin Kalinsky, Evanthia T. Roussos Torres, (unknown), (unknown), Kathy S. Albain, Amy S. Clark, Carla I. Falkson, Claudine Isaacs, Alexandra Thomas, Jennifer F. Tseng, (unknown), Hope S. Rugo, Nola M. Hylton, Douglas Yee, Christina Yau, Laura J. Esserman, (unknown)	10
6	Abstract PO2-16-05: ESR1 mutations (ESR1mut) in HR(+)HER2(-)patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for endocrine therapy (ET) resistance in real-world practice 2024 ·Cancer Research ·Manali Bhave, Júlia C.F. Quintanilha, Ryon P. Graf, (unknown), (unknown), Gerald Li, Alexa B. Schrock, Geoffrey R. Oxnard, Mia Levy, Kevin Kalinsky	0
7	Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice 2024 ·Breast Cancer Research and Treatment ·Manali Bhave, Júlia C.F. Quintanilha, Hanna Tukachinsky, Gerald Li, (unknown), Jeffrey S. Ross, Lincoln W. Pasquina, Richard S.P. Huang, Heather L. McArthur, Mia Levy, Ryon P. Graf, Kevin Kalinsky	11
8	Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis. 2024 ·Journal of Clinical Oncology ·Giuseppe Curigliano, Eva Ciruelos, Kevin Kalinsky, (unknown), Dave Nellesen, Priscilla Lopez, Samantha Kaufhold, (unknown), (unknown), Vaidyanathan Ganapathy, (unknown), Agnes Lteif, Peter A. Fasching, Erika Hamilton	9
9	Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States 2024 ·Breast Cancer Research and Treatment ·Kevin Kalinsky, Laura M. Spring, Clinton Yam, (unknown), Ιωάννα Ντάλλα, (unknown), (unknown), (unknown), Michael E. Stokes, Aliki Taylor, Rita Nanda	6
10	Abstract P6-01-20: Luminal androgen receptor subtype and M2 macrophage signatures strongly associate with low pathological complete response rates and poor outcomes in patients with triple negative breast cancer receiving neoadjuvant chemotherapy 2023 ·Cancer Research ·Jane Meisel, Eugene F. Douglass, Kevin Kalinsky, Lyra Griffiths, Zaibo Li, Xiaoxian Li	1
11	Abstract HER2-19: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score </25 randomized to endocrine therapy +/- chemotherapy: results from SWOG S1007 (RxPONDER) 2023 ·Cancer Research ·Laura M. Spring, William E. Barlow, Aditya Bardia, Priyanka Sharma, Lajos Pusztai, Gabriel N. Hortobágyi, Kevin Kalinsky	1
12	Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90) 2022 ·CardioVascular and Interventional Radiology ·(unknown), Keerthi Gogineni, Jane Meisel, (unknown), (unknown), (unknown), Zachary Bercu, Ila Sethi, (unknown), Jeffrey M. Switchenko, Jason Levy, Eddie K. Abdalla, (unknown), Kevin Kalinsky, Nima Kokabi	2
13	Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2− negative breast cancer 2021 ·Breast Cancer Research and Treatment ·(unknown), (unknown), Kevin Kalinsky	4
14	A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation 2018 ·Breast Cancer Research and Treatment ·Joyce O’Shaughnessy, Angela DeMichele, X. Cynthia, Paul Richards, Denise A. Yardley, Gail S. Wright, Kevin Kalinsky, Ronald G. Steis, Sami Diab, Gerard T. Kennealey, Ryan Geschwindt, Wei Jiang, Hope S. Rugo	35
15	Expanding the Criteria for Nipple-Sparing Mastectomy in Patients With Poor Prognostic Features 2017 ·Clinical Breast Cancer ·(unknown), Richard Ha, Christine H. Rohde, Jeffrey A. Ascherman, Robert T. Grant, (unknown), Eileen P. Connolly, Kevin Kalinsky, Sheldon Feldman, Bret Taback	26
16	¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors 2015 ·Journal of the Academy of Nutrition and Dietetics ·Heather Greenlee, (unknown), (unknown), (unknown), Isobel R. Contento, Wahida Karmally, John M. Richardson, Emerson A. Lim, Wei‐Yann Tsai, Katherine D. Crew, Matthew Maurer, Kevin Kalinsky, Dawn L. Hershman	58
17	¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer Survivors 2015 ·Journal of the Academy of Nutrition and Dietetics ·Heather Greenlee, (unknown), (unknown), (unknown), Isobel R. Contento, Wahida Karmally, John M. Richardson, Emerson A. Lim, Wei‐Yann Tsai, Katherine D. Crew, Matthew Maurer, Kevin Kalinsky, Dawn L. Hershman	20
18	Safety, Feasibility, and Biomarker Effects of High-Dose Vitamin D Supplementation Among Women at High Risk for Breast Cancer 2015 ·PubMed ·(unknown), Tong Xiao, (unknown), Mary Beth Terry, Matthew Maurer, Kevin Kalinsky, Sheldon Feldman, Lois Brafman, (unknown), (unknown)	26
19	Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology 2015 ·PLoS ONE ·Emily I. Chen, Katherine D. Crew, Meghna S. Trivedi, Danielle Awad, Matthew J. Maurer, Kevin Kalinsky, Antonius Koller, Purvi Patel, (unknown), Dawn L. Hershman	31
20	Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors 2013 ·Breast Cancer Research and Treatment ·Dawn L. Hershman, Heather Greenlee, Danielle Awad, Kevin Kalinsky, Matthew Maurer, Grace Kranwinkel, Lois Brafman, (unknown), Wei‐Yann Tsai, Alfred I. Neugut, Katherine D. Crew	98

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact